InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
05 janv. 2021 07h30 HE
|
InflaRx N.V.
JENA, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Q3 2020 Financial & Operating Results
29 oct. 2020 07h00 HE
|
InflaRx N.V.
Initiated Phase III part of the Phase II/III adaptive, randomized, controlled trial in patients with severe COVID-19 induced pneumoniaPublished encouraging data from Phase II part of COVID-19 trial in...
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
17 sept. 2020 07h30 HE
|
InflaRx N.V.
Thomas Taapken, Ph.D. appointed Chief Financial OfficerJordan Zwick promoted to Chief Strategy Officer JENA, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage...
InflaRx Announces Initiation of Phase III Part of Phase II/III Clinical Trial with IFX-1 in Severe COVID-19 Induced Pneumonia
14 sept. 2020 07h30 HE
|
InflaRx N.V.
First site initiated for enrollment in the NetherlandsRegulatory approval granted to start trial in GermanyAdditional sites to be added in the US, EU and other regionsEncouraging Phase II data...
InflaRx to Present at Upcoming Virtual Investor Events
06 août 2020 07h30 HE
|
InflaRx N.V.
JENA, Germany, Aug. 06, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Q2 2020 Financial & Operating Results
30 juil. 2020 07h30 HE
|
InflaRx N.V.
Announced encouraging results from the Phase II portion of the Phase II/III adaptive, randomized, controlled trial in patients with COVID-19 induced pneumonia, showing a trend in lower 28-day...
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
21 juil. 2020 07h30 HE
|
InflaRx N.V.
50% lower all-cause mortality rate and other efficacy trends were shown with IFX-1 in initial data from the randomized exploratory Phase II part of the Phase II/III trialSubject to regulatory...
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
17 juin 2020 07h30 HE
|
InflaRx N.V.
IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in...
InflaRx Reports Q1 2020 Financial & Operating Results
21 mai 2020 07h30 HE
|
InflaRx N.V.
End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of adaptive randomized...
InflaRx Reports Full Year 2019 Financial & Operating Results
29 avr. 2020 08h00 HE
|
InflaRx N.V.
End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of adaptive randomized trial in...